RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

Pfizer

Status: Completed

Conditions: Lymphoma

Treatments: Drug: Rituximab Pfizer; Drug: Rituxan

Study type: Observational

Funder types: Industry

Identifiers

NCT06790420

B3281009

Details and patient eligibility

About

To evaluate the incidence of the outcomes for the safety specifications in patients of Medical Data Vision database in Japan diagnosed with CD20 positive B-cell non- Hodgkin's lymphoma who were treated with Rituximab Pfizer to compare it with outcomes in patients who were treated with Rituxan from 01 January 2020 through 31 December 2024

Enrollment: 1 patient

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Have prescription of Rituximab Pfizer or Rituxan within the enrollment period (Index Date: first prescription date within the enrollment period).
2. Have diagnosis of CD20 positive B-cell non- Hodgkin's lymphoma on the index month or within 6 months before index date
3. Have at least 6 months of Look back period and at least one medical record prior to 7 months before the Index date.
4. Have not prescription of Rituximab product before index date(Comparative Analysis Set only).

Exclusion criteria

1. Have any diagnosis of other indications of rituximab products other than CD20 positive B-cell non- Hodgkin's lymphoma before index date .

Trial design

1 participants in 2 patient groups

Exposed group

Description:

patients treated with Rituximab Pfizer

Treatment:

Drug: Rituximab Pfizer

Comparative group

Description:

patients treated with Rituxan

Treatment:

Drug: Rituxan